Want to see HK:0690 full AI Analyst Report?
Uni-Bio Science Group Ltd. (0690) AI Stock Analysis
Top Page
Uni-Bio Science Group Ltd.
(HKEX:0690)
The score is driven primarily by solid financial performance (sustained profitability, strong margins, and manageable leverage) and attractive valuation (low P/E and strong dividend yield). These positives are tempered by weaker technicals (price below longer-term moving averages and negative MACD) and a key fundamental risk from the sharp 2025 revenue decline and uneven cash conversion.
Uni-Bio Science Group Ltd. (0690) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 394.10M
- Dividend Yield
- 4.74%
- Average Volume (3M)
- 3.74M
- Price to Earnings (P/E)
- 8.1
- Beta (1Y)
- -0.15
- Revenue Growth
- -6.75%
- EPS Growth
- -47.06%
- Country
- Hong Kong
- Employees
- 543
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Uni-Bio Science Group Ltd. Business Overview & Revenue Model
Company Description
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions a...
How the Company Makes Money
The company makes money primarily by commercializing its biologic drug products, with revenue generally generated from the sale of finished pharmaceutical products (and, where applicable, related distribution/commercialization activities) into its se...
Uni-Bio Science Group Ltd. Financial Statement Overview
Summary
Strong profitability and margins following a multi-year turnaround (gross margin ~low-80% in 2023–2025; EBIT margin ~15–17%; net margin mid-teens) and generally conservative leverage with strong ROE (low-to-mid 20% in 2023–2025). Offsetting these positives, 2025 revenue declined sharply (~57%), and cash conversion has been uneven with limited visibility from unusable 2025 cash-flow ratio data.
Income Statement
74PositiveBalance Sheet
78PositiveCash Flow
66Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 549.77M | 586.21M | 552.98M | 484.72M | 440.32M | 353.40M |
| Gross Profit | 454.71M | 487.56M | 461.07M | 392.82M | 334.88M | 277.01M |
| EBITDA | 75.31M | 118.75M | 113.56M | 93.56M | 61.21M | 1.31M |
| Net Income | 48.54M | 93.33M | 82.77M | 70.88M | 38.51M | -19.59M |
Balance Sheet | ||||||
| Total Assets | 605.53M | 579.80M | 517.55M | 409.99M | 292.47M | 267.59M |
| Cash, Cash Equivalents and Short-Term Investments | 158.87M | 179.89M | 183.90M | 129.24M | 98.22M | 83.61M |
| Total Debt | 85.64M | 97.76M | 115.19M | 56.30M | 22.67M | 5.60M |
| Total Liabilities | 156.82M | 166.56M | 191.91M | 152.82M | 97.72M | 93.29M |
| Stockholders Equity | 448.71M | 413.25M | 325.64M | 257.17M | 194.75M | 174.31M |
Cash Flow | ||||||
| Free Cash Flow | -8.76M | 38.12M | 28.71M | 39.11M | 20.23M | 3.61M |
| Operating Cash Flow | 43.47M | 90.34M | 66.71M | 98.85M | 48.66M | 12.04M |
| Investing Cash Flow | -37.81M | 66.36M | -168.07M | -76.14M | -27.03M | 42.12M |
| Financing Cash Flow | -13.90M | -33.81M | 27.79M | 24.51M | 2.58M | 478.00K |
Uni-Bio Science Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0690, the sentiment is Positive. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 53.36 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0690.
Uni-Bio Science Group Ltd. Peers Comparison
Overall Rating
- HK:069071Outperform
HK:699870Outperform
HK:218157Neutral
HK:213742Neutral
HK:249641Neutral
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0690 | 71Outperform | HKD 393.17M | 8.15 | 11.26% | 4.74% | -6.75% | -47.06% |
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:2181 | 57Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2137 | 42Neutral | HKD 708.65M | -3.48 | -7.32% | ― | ― | 51.71% |
| HK:2496 | 41Neutral | HKD 1.05B | -13.87 | 85.52% | ― | -55.22% | 57.76% |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0690 | Uni-Bio Science Group Ltd. | 0.07 | -0.06 | -45.90% | |
| HK:2137 | Brii Biosciences Limited | 0.98 | -0.91 | -48.15% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:2496 | Wuhan YZY Biopharma Co., Ltd. Class H | 4.00 | -3.01 | -42.94% |
Uni-Bio Science Group Ltd. Corporate Events
Uni-Bio Science Wins Strong Shareholder Backing for Executive Option Grants
Independent shareholders of Uni-Bio Science Group Ltd. have approved a series of share option grants to key executives at an extraordinary general meeting held on 19 August 2026. Four ordinary resolutions authorizing options over a total of 300 milli...
Uni-Bio Science Sets August Board Meeting to Approve Interim Results
Uni-Bio Science Group Limited has scheduled a board meeting for 26 August 2026 at its registered office to review and approve the interim financial results for the six months ended 30 June 2026. Following board approval, the company plans to publish...
Uni-Bio Science Flags Profit Drop as Tax and Pricing Pressures Bite
Uni-Bio Science Group Limited has warned that its net profit for the six months ended 30 June 2026 is expected to drop to about HK$30 million from HK$75.96 million a year earlier, citing higher value-added tax rates on biological products in China an...
Uni-Bio Science to Seek Shareholder Approval for Large Executive Option Grant
Uni-Bio Science Group Limited has called an extraordinary general meeting for 19 August 2026 at its Hong Kong Science Park offices. The meeting will be open to registered shareholders, who may appoint proxies, with the share register closed from 14 t...
Uni-Bio Science Grants 300 Million Share Options to Senior Executives
Uni-Bio Science Group Ltd. has granted share options over 300 million shares to four senior executives, including its chairman, chief executive officer, chief operating officer and chief business officer, under its existing share option scheme. The o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 09, 2026